July 14, 2020

Volume X, Number 196

July 14, 2020

Subscribe to Latest Legal News and Analysis

July 13, 2020

Subscribe to Latest Legal News and Analysis

Year in Review: The Most Popular IP Posts of 2019

As 2020 begins and intellectual property (IP) strategies are being developed for the new year, it is a good time to reflect on what IP issues were prominent in 2019.  According to many readers, hot topics included § 112 written description, prosecution history estoppel, and venue in the wake of TC Heartland.

Here are 2019’s top 5 most popular Mintz IP posts:

1. Written Description in Amgen v. Sanofi: Is the Federal Circuit Possessed? Will SCOTUS Grant Certiorari? – This article focuses on the Federal Circuit’s decision in Amgen v. Sanofi regarding the 35 U.S.C. § 112 written description requirement with respect to antibody claims and the Supreme Court’s potential for granting cert.  Cert was denied, so the Federal Circuit overturning of the “newly characterized antigen test” stands.

2. Effect of A Restriction Requirement on Prosecution History Estoppel – This article discusses how the Federal Circuit’s decision in UCB, Inc. v. Watson Laboratories Inc. helps highlight that while an examiner’s decision to issue a Restriction Requirement may in some circumstances lead to prosecution history estoppel preventing a later application of the doctrine of equivalents, it is not an automatic danger sign that future claim scope will be limited.

3. Understanding the USPTO’s Interpretation of 35 U.S.C. § 112 for Computer-Implemented Functional Claim Limitations – The U.S. Patent and Trademark Office (USPTO) held a webinar in June 2019 entitled “Examining Computer-Implemented Functional Claim Limitations for Compliance with 35 U.S.C. § 112” in light of § 112 USPTO Guidance issued earlier in the year.  This article summarizes the webinar’s highlights.

4. Dueling Declaratory Judgment Suits Result in a Dismissal and Boomerang Transfer Back to the First-filed Forum Under TC Heartland – This article discusses the Eastern District of Texas’s decision in Apicore v. Beloteca, which held that while the court could exercise personal jurisdiction over a generic drug manufacturer in connection with the patentee’s action seeking a declaratory judgment of noninfringement, venue was not appropriate in the Eastern District of Texas under the applicable patent venue statute.

5. Representations Made by a Patentee during Foreign Prosecution May Be Used in Claim Construction for U.S. Patents – When looking to construe U.S. patent claims from a litigation or diligence perspective, foreign prosecution history could be an important repository for analysis.  This article discusses Federal Circuit case law regarding when the prosecution history of a related foreign patent or patent application must be considered and limits on its consideration.

©1994-2020 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. All Rights Reserved.National Law Review, Volume X, Number 6


About this Author

Christina Sperry, Mintz Levin Law Firm, Boston, Medical Tech and Intellectual Property Law Attorney

Christina is an experienced patent attorney whose clients are focused in the medical technology space, from start-ups to large corporations and academic institutions. She advises on patent preparation and prosecution and provides opinions on infringement, validity, and right-to-use for clients in the US and internationally.

The areas of technology in which Christina is particularly focused include mechanical, electrical, and electro-mechanical technical fields such as medical and surgical instruments and devices including endoscopic, soft tissue...